Company Filing History:
Years Active: 2006
Title: Angelika Böttger: Innovator in Cancer Research
Introduction
Angelika Böttger is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of cancer research, particularly in the development of therapeutic compounds. Her work focuses on the interaction between the oncogene protein MDM2 and the tumor suppressor protein p53.
Latest Patents
Angelika Böttger holds a patent for "Inhibitors of the interaction between P53 and MDM2." This invention relates to compounds capable of binding to the oncogene protein MDM2. The patent outlines processes for the preparation of such compounds, pharmaceutical preparations comprising these compounds, and their uses in therapeutic treatments. The invention also includes methods and compounds for inhibiting the growth of tumor cells that express the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2. She has 1 patent to her name.
Career Highlights
Böttger is associated with Cancer Research Campaign Technology Limited, where she continues her innovative work in cancer therapeutics. Her research has the potential to significantly impact the treatment of various cancers, providing new avenues for therapeutic intervention.
Collaborations
Throughout her career, Angelika Böttger has collaborated with notable scientists, including David Philip Lane and Volker Böttger. These collaborations have enriched her research and contributed to advancements in cancer treatment.
Conclusion
Angelika Böttger is a key figure in the field of cancer research, with her innovative patent addressing critical interactions in tumor biology. Her work exemplifies the importance of scientific innovation in the fight against cancer.